Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 95

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 95
---
 sublicensing arrangements in the future, but we may not realize the benefits of these arrangements. We intend to form or seek strategic alliances, create joint ventures or collaborations, acquire complimentary products, IP rights, technology or businesses or enter into additional licensing arrangements with unrelated parties that we determine may complement or augment our development and commercialization efforts with respect to our drug and diagnostics technology candidates. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business. We will face significant competition in seeking appropriate strategic partners and the negotiation process is likely to be time-consuming, costly and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or another alternative arrangement for any of our drug and diagnostics technology candidates because their state of development may be deemed to be too early for collaborative effort and others may not view our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we enter into an agreement with a collaboration partner or sublicensee for development and commercialization of a drug or diagnostics technology candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the unrelated-party. Further, even if we enter into a collaboration involving any of our drug and diagnostics technology candidates, the arrangement will be subject to numerous risks, which may include the following:

| ● | the collaborators will likely have significant discretion in                   
 determining the efforts and resources that they will apply to a collaboration; |

| ● | the collaborator may ultimately choose not pursue development                                                                                 
 and commercialization of our drug or diagnostics technology candidates or may elect not to continue or renew development or commercialization 
 programs, based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drugs, availability         
 of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;                 |

| ● | the collaborator may delay clinical trials, provide insufficient                                                                        
 funding for a clinical trial, stop a clinical trial, abandon a drug or diagnostics technology candidate, repeat or conduct new clinical 
 trials, or require a new formulation of a drug or diagnostics technology candidate for clinical testing;                                |

| ● | the collaborator could independently develop, or develop with                                   
 unrelated parties, drugs that compete directly or indirectly with our drugs or drug candidates; |

| ● | the collaborator with marketing and distribution rights to one                         
 or more drugs may not commit sufficient